Chinook Therapeutics, Inc., now a Novartis Company, is a clinical-stage biopharmaceutical company based in Seattle, WA. They specialize in the discovery, development, and commercialization of precision medicines for rare and severe chronic kidney diseases, with a particular focus on IgA nephropathy. With a strong pipeline of innovative therapies, Chinook is dedicated to changing the course of kidney care and improving the lives of patients suffering from these debilitating conditions.
As a leader in the field, Chinook Therapeutics is committed to advancing the understanding and treatment of chronic kidney diseases through rigorous scientific research and clinical trials. Their precision medicines, such as Atrasentan, Zigakibart BION-1301, and CHK-336, offer promising solutions for patients in need. With a patient-centric approach and a dedication to scientific excellence, Chinook Therapeutics is at the forefront of transforming kidney care and bringing hope to those affected by these challenging conditions.
Generated from the website